Skip to main content
. 2011 Sep 21;9:156. doi: 10.1186/1479-5876-9-156

Figure 2.

Figure 2

SLC22A18 expression in patients stratified by tumor grade and recurrence. (A) Semiquantitative analysis of SLC22A18 immunohistochemical staining in low grade (WHO I-II) glioma and high grade (WHO III-IV) glioma. (B) Semiquantitative analysis of SLC22A18 immunohistochemical staining in gliomas which recurred and those which did not recur within six months after surgery, P values compare overall SLC22A18 expression in each group.